Piper Sandler Upgrades Palisade Bio (NASDAQ:PALI) to Strong-Buy

Palisade Bio (NASDAQ:PALI) was upgraded by stock analysts at Piper Sandler to a “strong-buy” rating in a report issued on Monday,Zacks.com reports.

Several other research analysts also recently weighed in on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Palisade Bio in a research note on Wednesday, October 8th. Wall Street Zen lowered shares of Palisade Bio from a “hold” rating to a “sell” rating in a research report on Saturday, December 20th. Finally, Citigroup restated a “buy” rating on shares of Palisade Bio in a research report on Tuesday, November 11th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Palisade Bio currently has a consensus rating of “Moderate Buy” and an average price target of $20.50.

Palisade Bio Price Performance

Shares of PALI opened at $2.48 on Monday. Palisade Bio has a 1-year low of $0.53 and a 1-year high of $2.59. The stock has a market cap of $369.52 million, a price-to-earnings ratio of -1.17 and a beta of 1.54. The firm has a 50 day simple moving average of $1.95 and a 200-day simple moving average of $1.28.

Palisade Bio (NASDAQ:PALI) last announced its earnings results on Monday, November 10th. The company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.06). On average, equities analysts expect that Palisade Bio will post -12.43 earnings per share for the current fiscal year.

Palisade Bio Company Profile

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.